Supplementary Figure S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target

Takuma Yoshimura; Takashi Kamatani; Aki Ookubo; Mio Takahashi; Manabu Itoh; Toshiki Ebisudani; Yohei Masugi; Tomomi Toyonaga; Junko Hamamoto; Keiko Saotome; Kensuke Sakai; Tomoko Yoshihama; Nobuko Moritoki; Shinsuke Shibata; Hiroyuki Yasuda; Toshiro Sato; Taka-Aki Sato; Daisuke Aoki; Wataru Yamagami; Tatsuhiko Tsunoda; Tatsuyuki Chiyoda

doi:10.1158/2767-9764.29645823

Key Points

Main finding highlights vulnerability of clear cell ovarian cancer organoids to proteasome inhibitors and dinaciclib.
Evidence from QIAGEN Ingenuity Pathway Analysis supports the role of agr2 as a therapeutic target in the cancer model.
Analysis utilized DESeq2 with criteria of absolute logFC > 1.5 and p < 0.0005 to identify gene expression changes.
This research advances understanding of potential treatments for clear cell ovarian cancer, focusing on the role of agr2 and drug efficacy.

Implication

High-throughput drug screening identifies agr2 as a therapeutic target and reveals vulnerability to proteasome inhibitors and dinaciclib in clear cell ovarian cancer organoids, suggesting potential new treatments.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yoshimura et al. (2025) studied this question.

synapsesocial.com/papers/689a0f8de6551bb0af8d0d5b https://doi.org/10.1158/2767-9764.29645823

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers